Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Show More...

  • Website https://www.agios.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 27.40 EUR
  • Last Updated 29-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM
    Earnings Per Share USD -1.15 -1.17 -2.83 -1.59 -3.15 -5.07 -6.75 -6.03 -6.86 -5.86
    Dividends USD
    Payout Ratio % *
    Shares Mil 23.0 23.0 15.0 34.0 37.0 39.0 47.0 57.0 60.0 63.0
    Book Value Per Share * EUR 3.32 4.61 9.12 8.99 7.72 11.42 5.86 8.19
    Free Cash Flow Per Share * EUR -1.3 -1.66 -1.83 1.2 -4.97 -4.96 -5.46
    Return on Assets % -13.78 -16.47 -25.76 -15.44 -25.82 -38.2 -51.02 -46.99 -47.05 -44.23
    Financial Leverage (Average) 1.53 1.16 1.22 1.73 1.64 1.25 1.39 1.27
    Return on Equity % -146.55 -19.25 -30.6 -56.41 -85.73 -65.1 -61.97 -57.59
    Return on Invested Capital % -146.67 -19.32 -30.85 -57.12 -87.4 -68.2 -54.82 -51.96
    Interest Coverage
    Current Ratio 3.96 3.71 4.6 5.89 6.38 6.33 4.69 6.56 6.59 8.41
    Quick Ratio 3.72 3.64 4.53 5.81 6.21 6.22 4.51 6.37 6.25 7.85
    Debt/Equity 0.17 0.17